Natriuretic peptide receptor-3 gene (NPR3): Nonsynonymous polymorphism results in significant reduction in protein expression because of accelerated degradation

Circulation: Cardiovascular Genetics

Volumn 6, Issue 2, 2013, Pages 201-210

  Pereira, Naveen L ^a   Lin, Dong ^a   Pelleymounter, Linda ^b   Moon, Irene ^b   Stilling, Gail ^a   Eckloff, Bruce W ^b   Wieben, Eric D ^b   Redfield, Margaret M ^a   Burnett, John C ^a   Yee, Vivien C ^c   Weinshilboum, Richard M ^b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Natriuretic peptide receptor 3; Natriuretic peptides; Pharmacogenetics; Polymorphism

Indexed keywords

DNA;

AFRICAN AMERICAN; ARTICLE; ASIAN AMERICAN; AUTOPHAGY; CONTROLLED STUDY; EUROPEAN AMERICAN; EXON; GENE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; NATRIURETIC PEPTIDE RECEPTOR 3 GENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN STABILITY; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING;

EID: 84878087046     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.112.964742     Document Type: Article

References (36)

1. Boerrigter G, Costello-Boerrigter LC, Burnett JC Jr. Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail Clin. 2009;5:501-514.
2. Rademaker MT, Charles CJ, Kosoglou T, Protter AA, Espiner EA, Nicholls MG, et al. Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure. Am J Physiol. 1997;273(5 pt 2):H2372-H2379.
3. He X-l, Chow D-c, Martick MM, Christopher Garcia K. Allosteric activation of a spring-loaded natriuretic peptide receptor dimer by hormone. Science. 2001;293:1657-1662.
4. Potter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J. 2011;278:1808-1817.
5. Murthy KS, Makhlouf GM. Identification of the G protein-activating domain of the natriuretic peptide clearance receptor (NPR-C). J Biol Chem. 1999;274:17587-17592.
6. Estrada K, Krawczak M, Schreiber S, van Duijn K, Stolk L, van Meurs JB, et al. A genome-wide association study of northwestern Europeans involves the C-type natriuretic peptide signaling pathway in the etiology of human height variation. Hum Mol Genet. 2009;18:3516-3524.
7. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, et al. Metaanalysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet. 2011;43:531-538.
8. Sarzani R, Strazzullo P, Salvi F, Iacone R, Pietrucci F, Siani A, et al. Natriuretic peptide clearance receptor alleles and susceptibility to abdominal adiposity. Obes Res. 2004;12:351-356.
9. Saulnier PJ, Roussel R, Halimi JM, Lebrec J, Dardari D, Maimaitiming S, et al; SURDIAGENE, DIAB2NEPHROGENE, and DIABHYCAR study groups. Impact of natriuretic peptide clearance receptor (NPR3) gene variants on blood pressure in type 2 diabetes. Diabetes Care. 2011;34:1199-1204.
10. The International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103-109.
11. He XL, Dukkipati A, Garcia KC. Structural determinants of natriuretic peptide receptor specificity and degeneracy. J Mol Biol. 2006;361:698-714.
12. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60(pt 12 Pt 1):2126-2132.
13. Kraulis PJ. Molscript: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr. 1991;24:946-950.
14. Merritt EA, Bacon DJ. Raster3D: photorealistic molecular graphics. Meth Enzymol. 1997;277:505-524.
15. Tajima F. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics. 1989;123:585-595.
16. Hartl DL, Clark AG. Principles of Population Genetics. Sunderland, MA: Sinauer Associates, Inc; 1997:96-106.
17. Hedrick PW. Genetics of Populations. Sundbury, MA: Jones and Bartlett Publishers; 2000.
18. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
19. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002;70:425-434.
20. Zhou H, Murthy KS. Identification of the G protein-activating sequence of the single-transmembrane natriuretic peptide receptor C (NPR-C). Am J Physiol, Cell Physiol. 2003;284:C1255-C1261.
21. Consortium. GP, Durbin RM, Abecasis GR, Altshuler DL, Auton A, Brooks LD, et al. A map of human genome variation from populationscale sequencing. Nature. 2010;467:1061-1073.
22. Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet. 2006;7:781-791.
23. Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, et al Pharmacogenetics Research Network. Pharmacogenomics: challenges and opportunities. Ann Intern Med. 2006;145:749-757.
24. Wang L, Yee VC, Weinshilboum RM. Aggresome formation and pharmacogenetics: sulfotransferase 1A3 as a model system. Biochem Biophys Res Commun. 2004;325:426-433.
25. Reinstein E, Ciechanover A. Narrative review: protein degradation and human diseases: the ubiquitin connection. Ann Intern Med. 2006;145:676-684.
26. Clague MJ, Urbé S. Ubiquitin: same molecule, different degradation pathways. Cell. 2010;143:682-685.
27. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science. 2006;314:1930-1933.
28. Zhu X, Young JH, Fox E, Keating BJ, Franceschini N, Kang S, et al. Combined admixture mapping and association analysis identifies a novel blood pressure genetic locus on 5p13: contributions from the CARe consortium. Hum Mol Genet. 2011;20:2285-2295.
29. Fox AA, Collard CD, Shernan SK, Seidman CE, Seidman JG, Liu KY, et al. Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass grafting. Anesthesiology. 2009;110:738-747.
30. Coffman TM. Under pressure: the search for the essential mechanisms of hypertension. Nat Med. 2011;17:1402-1409.
31. Ji W, Foo JN, O'Roak BJ, Zhao H, Larson MG, Simon DB, et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet. 2008;40:592-599.
32. Bodmer W, Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet. 2008;40:695-701.
33. Rubattu S, Sciarretta S, Morriello A, Calvieri C, Battistoni A, Volpe M. NPR-C: a component of the natriuretic peptide family with implications in human diseases. J Mol Med. 2010;88:889-897.
34. Matsukawa N, Grzesik WJ, Takahashi N, Pandey KN, Pang S, Yamauchi M, et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci USA. 1999;96:7403-7408.
35. Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker- Foster C, et al. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA. 2008;299:296-307.
36. Pereira NL, Aksoy P, Moon I, Peng Y, Redfield MM, Burnett JC Jr, et al. Natriuretic peptide pharmacogenetics: membrane metallo- endopeptidase (MME): common gene sequence variation, functional characterization and degradation. J Mol Cell Cardiol. 2010;49:864-874.